Fig. 2.

Time to SARS-CoV-2 clearance (mITT population) based on (a) qualitative RT-PCR and (b) quantitative PCR. Shown are Kaplan–Meier curves. Time to clearance was defined as the time to the first negative (a) qualitative or (b) quantitative SARS-CoV-2 RT-PCR test (collected post-baseline on days 3, 7, 10, 14, 21, and 28), without any subsequent positive SARS-CoV-2 RT-PCR test. Patients who withdrew from the study were censored on the day of withdrawal; patients with missing data were censored on the day of the last available data; patients without any post-baseline data were censored on day 1. mITT, modified intention-to-treat; ASAQ, artesunate-amodiaquine; PA, pyronaridine-artesunate; FPV + NTZ, favipiravir plus nitazoxanide; SOF-DCV, sofosbuvir-daclatasvir; NE, non-evaluable.